Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Crinetics Pharmaceuticals Inc.
M.D. Anderson Cancer Center
ViroMissile, Inc.
Exelixis
Cedars-Sinai Medical Center
Boston Scientific Corporation
SystImmune Inc.
Hoffmann-La Roche
Changi General Hospital
UNICANCER
AccSalus Biosciences, Inc.
MedSIR
Hutchmed
National Cancer Institute (NCI)
University of Sao Paulo
Federation Francophone de Cancerologie Digestive
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Peking Union Medical College Hospital
H. Lee Moffitt Cancer Center and Research Institute
Institut Bergonié
Provectus Pharmaceuticals
Boston Scientific Corporation
Amgen
Xiangya Hospital of Central South University
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Yale University
Yale University
Massachusetts General Hospital
Novartis
GERCOR - Multidisciplinary Oncology Cooperative Group
INSYS Therapeutics Inc
Peking University
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
European Organisation for Research and Treatment of Cancer - EORTC
Vanderbilt-Ingram Cancer Center
National Institutes of Health Clinical Center (CC)
European Organisation for Research and Treatment of Cancer - EORTC